Commercial
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
The antibody-drug conjugate pipeline has more than doubled to 895 candidates since 2023, with DNA topoisomerase I overtaking HER2 as the dominant target.
Cell and gene therapy is shifting into a new phase, as maturing commercial launches, rising big pharma participation and regulatory momentum replace hype and skepticism.
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
From biotech experiments to billion-dollar breakthroughs, Noubar Afeyan has built a career out of turning bold ideas into transformative companies.
A search bar has become one of the most powerful gateways into modern healthcare. The result is a gray zone where advertising practices, consumer trust and public health collide, raising questions about whether digital marketing has outpaced regulation.
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
The company reported its first full quarter of sales for Palsonify, which drew in revenues of more than $5m, beating consensus estimates. It also released Phase II data for atumelnant in congenital adrenal hyperplasia.
While US sales of the Sandoz-partnered Cimerli (ranibizumab) biosimilar are paused, Formycon has found a new partner in Zydus for its recently approved second Lucentis rival.